Related references
Note: Only part of the references are listed.Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
Don Husereau et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Yan Li et al.
FRONTIERS IN PHARMACOLOGY (2022)
Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
Yan Li et al.
CANCER (2022)
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Miranda Gogishvili et al.
NATURE MEDICINE (2022)
Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis
Yan Li et al.
FRONTIERS IN ONCOLOGY (2022)
Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Yan Li et al.
FRONTIERS IN PHARMACOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
Gerasimos Konidaris et al.
VALUE IN HEALTH (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
Eunae Jeong et al.
FRONTIERS IN ONCOLOGY (2021)
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma A Network Meta-analysis and Cost-effectiveness Analysis
Rui Pei et al.
JAMA NETWORK OPEN (2021)
Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
Liting Wang et al.
ADVANCES IN THERAPY (2021)
Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions
Aakash Desai et al.
ECLINICALMEDICINE (2020)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
Ralph P. Insinga et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades
Tao Lu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Assessment of costs associated with adverse events in patients with cancer
William Wong et al.
PLOS ONE (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Health state utilities in non-small cell lung cancer: An international study
Beenish Nafees et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Socioeconomic disparities, financial toxicity, and opportunities for enhanced system efficiencies for patients with cancer
Daniel E. Abbott et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Elena Burova et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy
Li Ma et al.
CHINESE JOURNAL OF CANCER (2017)
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Scott D. Ramsey et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion
Karoline Freeman et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
Analysis of Stage and Clinical/Prognostic Factors for Lung Cancer From SEER Registries: AJCC Staging and Collaborative Stage Data Collection System
Vivien W. Chen et al.
CANCER (2014)
Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma
Curtis R. Pickering et al.
CLINICAL CANCER RESEARCH (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
Andrew J. Murphy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience
S. Yousuf Zafar et al.
ONCOLOGIST (2013)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Health state utilities for non small cell lung cancer
Beenish Nafees et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2008)
Share Paper
